AMX-883, Amphista’s first asset to enter the clinic, is a potent, selective, orally bioavailable DCAF16-mediated BRD9 degrader targeting acute myeloid leukemia (AML)
The first-in-human ‘BRAMLIE’ (BR(D9) AML Interventional Evaluation) trial will assess the safety, pharmacokinetics and preliminary efficacy of AMX-883 monotherapy in participants with AML and high-risk myelodysplastic syndrome (MDS)
AMX-883 demonstrates karyotype-independent pro-differentiation activity pre-clinically, with trial enrolling patients regardless of mutational status
Cambridge, UK, 12 October 2026: Amphista…
With plenty happening across the life sciences sector, there’s always an opportunity to keep learning, build new skills and stay connected. We’ve brought together our latest learning opportunities, designed to support professionals at every career stage, alongside our popular in-house training, offering practical and relevant learning tailored to the needs of teams across academia and industry. ________________________________________________
Upcoming Featured Opportunities
20 October 2026 | Enabling Membrane Protein CryoEM, and beyond, with Polymer Nanodiscs: A TRPML3 Case Study22…
The fifth edition of o2h Technology’s Tech Kickstarter Competition has been launched.The contest has been helping seed and early-stage companies to accelerate their digital progress by transforming innovative ideas into market-ready products, using agentic AI, MVP development, web and mobile applications, and intelligent automation. More than 100 start-up applications have previously applied to the Tech Kickstarter competition, with 13 winners selected, spanning life sciences, tech and AI, and green innovation.Prashant Shah, Co-founder and Co-CEO at o2h Group, said:Every year, we see…
Prof Dame Carol Robinson (University of Oxford), Dr Andrew Doré (Isomorphic Labs) and Prof Paula Booth (King’s College London) to lead event taking place from 10–11 November at GSK Stevenage
Programme to focus on AI, machine learning and data-driven approaches across protein design, characterisation and therapeutic development
Cambridge, UK, 8 October 2026: ELRIG, a not-for-profit, volunteer-led organisation dedicated to the global drug discovery community, and The Protein Society, an international, not-for-profit, scholarly society, with the mission to provide forums for the advancement of…
Amsbio has expanded its range of high-quality FFPE tissues and controls specifically designed to support biomarker discovery, histopathology, translational research and assay development.
Although the tissue structure in FFPE samples is maintained for histological analysis, damage to the RNA incurred through the fixation, embedding, and storage processes advances with time and storage temperature. Sub-optimal tissue quality is one of the leading causes of misleading biomarker research.
Including normal adjacent tissues, special disease samples and over 30 types of human cancer tissues (…
Celebrating the Innovators Shaping the Future of Life Sciences at GenesisThe shortlist for the five main One Nucleus Awards 2026 has been announced, thus confirming the line up for the Company Showcase stream at Genesis, on 10 December 2026 at 1 Wimpole Street, London.
The selected companies are competing for Best Clinical Stage R&D Company; Best Use of New Technology; Best Industry-Academia Deal; Best Non-Therapeutic Company and Best Pre-Clinical Stage Company.
Complementing the above awards, we will be recognising outstanding achievements across the remainder of life sciences…
Scientists can now connect company-approved AI providers such as Claude Code and GitHub Copilot directly to Flare, helping teams set up, execute, and analyze complex computational chemistry workflows in minutes not hours.CAMBRIDGE, UK, October 6th 2026 – Drug discovery teams are under pressure to evaluate more molecules, deliver results faster and achieve more with the resources they already have. AI can help, but scientists do not want another standalone agent to learn, validate and govern. They need a practical way to use the AI tools they already trust within the scientific workflows they…
October 6, 2026
Tony Jones CEO, One Nucleus
Welcome to the Autumn eNews edition from One Nucleus. Autumn seems to get a mixed reputation. Some suffer from the decreased daylight, the frights of Halloween and loud bangs of November 5th. Others welcome the transition to the cosy evening meetings, October treats and spectacular fireworks, all leading to Thanksgiving and then Christmas. Whilst for some, it feels little is changing enough in the sector as investment remains selective and later-stage, and times are tough.
We need change! One Nucleus embraces the…
LONDON, UK; HELSINKI, FINLAND; and NAPLES, ITALY – October 6, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search assignment for Valo Therapeutics Group ("Valo Therapeutics") and is pleased to announce the placement of Carlos de Sousa, M.D., MBA, as Chief Executive Officer.Valo Therapeutics is a clinical-stage biotechnology company developing novel immunotherapies for cancer. The Company's proprietary PeptiCRAd platform combines oncolytic adenoviruses with tumor-associated peptides to…
Cancer Research UK have signed an agreement with ORIC Pharmaceuticals, Inc. to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy, into clinical development.
Under the agreement, Cancer Research UK’s Centre for Drug Development (CDD) will fully fund, sponsor, design and execute a Phase 1/2 clinical trial of ORIC-259, including CTA-enabling studies, for patients with cancer. ORIC retains an option to reacquire rights to ORIC-259 following Phase 1/2 data, with Cancer Research UK eligible to receive downstream milestone payments and royalties. Cancer Research Horizons, Cancer…